Results 291 to 300 of about 58,205 (308)

RNaseH2 inhibition potentiates temozolomide response in patient derived glioblastoma cells. [PDF]

Sci Rep
Kissova M, Martinez Segarra J, Iveland TS, Vestvik M, Ravlo E, Wang W, Hagen L, Liabakk NB, Camara-Quilez M, Arano Barenys M, Solheim O, Hoff BH, Sundby E, Bjørås M, Slupphaug G, Visnes T, Brambilla A.   +16 more
europepmc   +1 more source

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development. [PDF]

NPJ Precis Oncol
Nakazawa M, Arif W, Baraban E, Matoso A, Hallab E, Kartalia E, Azad NS, Baretti M, Zabransky DJ, Anders RA, Oshima K, Yarchoan M.   +11 more
europepmc   +1 more source

Gliome mit IDH1-Mutation: Progression kann mit spezifischer IDH1-Inhibition aufgehalten werden

Deutsches Ärzteblatt Online
openaire   +1 more source

Pediatric gliomas. Analysis of IDH1 mutations

, 2012
Suñol M, Ribalta-Farrés MT, Cruz-Martínez O, Cusi V, Rovira-Zurriaga C, Jou-Munoz C, Galván P, Rodriguez E, de Torres C   +8 more
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Radioprotection of IDH1 -Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198

Cancer Research, 2015
Abstract Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-molecule inhibitors of IDH1R132H that are being developed for cancer therapy ...
Molenaar, R.J., Botman, D., Smits, M.A., Hira, V.V., Lith, S.A.M. van, Stap, J., Henneman, P., Khurshed, M., Lenting, K., Mul, A.N., Dimitrakopoulou, D., Drunen, C.M. van, Hoebe, R.A., Radivoyevitch, T., Wilmink, J.W., Maciejewski, J.P., Vandertop, W.P., Leenders, W.P.J., Bleeker, F.E., Noorden, C.J.F. van   +19 more
openaire   +4 more sources

Targeting IDH1/IDH2 mutations in gliomas

Current Opinion in Neurology, 2022
Purpose of review Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2–3 diffuse glioma and the most powerful positive prognostic factor for survival in gliomas. The purpose is to review experimental therapeutic approaches targeting IDH mutations in
openaire   +2 more sources

IDH1/2 mutation detection in gliomas

Brain Tumor Pathology, 2014
Somatic mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) are strongly associated with pathological subtypes, genetic profiles, and clinical features in gliomas. The IDH1/2 status is currently regarded as one of the most important molecular markers in gliomas and should be assessed accurately and robustly.
Hideyuki, Arita, Yoshitaka, Narita, Akihiko, Yoshida, Naoya, Hashimoto, Toshiki, Yoshimine, Koichi, Ichimura   +5 more
openaire   +2 more sources